Palantir stock is down significantly since I warned investors not to buy.

AI-generated source summary

The analyst reaffirms his previous November 3, 2025, recommendation against purchasing Palantir stock. While acknowledging the company's strong business performance, including accelerating revenue growth, expanding profit margins, increasing cash flow from operations to sales, and a high return on invested capital, his advice stems from valuation concerns. On November 3, 2025, Palantir traded at approximately $213 per share. By November 19, 2025, the stock had declined to $166.49, despite a year-to-date gain of over 118% and a six-month increase of 31%. The analyst's updated discounted cash flow (DCF) model, which incorporates upgraded free cash flow expectations and a reduced risk profile via a lower beta, yields an intrinsic value per share of $70.52. This intrinsic value is significantly below the current market price of $165.49, indicating the stock is overvalued. Free cash flow is projected to increase robustly from $1.93 billion in 2025 to $33.49 billion by 2034, with a long-term growth rate estimated at 6%. Despite these excellent prospects, the analyst maintains a 'Hold/Market Perform' rating, advising investors to await a lower price, as the company's future growth is already largely priced into its current valuation.

AI-generated summary based on the source content.

Evidence and evaluation progress

1. Original source published

   20 Nov 2025, 23:09 UTC

   The analyst published the original source item.

2. Source recorded by Tahlil Plus

   18 May 2026, 20:23 UTC

   The public source was preserved as the evidence record for this case.

3. Market predictions extracted

   18 May 2026, 20:48 UTC

   1 eligible signal linked to this case.

4. Outcome tracking started

   19 May 2026, 02:08 UTC

   Tahlil Plus began monitoring the extracted predictions.

5. Live evaluation in progress

   01 Aug 2026, 01:45 UTC

   1 signal remains active.